Abstract

The aim of this study was to reduce the door-to-needle (DTN) time of intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) through a comprehensive, hospital-based implementation strategy. The intervention involved a systemic literature review, identifying barriers to rapid IVT treatment at our hospital, setting target DTN time intervals, and building an evolving model for IVT candidate selection. The rate of non-in-hospital delay (DTN time ≤ 60 min) was set as the primary endpoint. A total of 348 IVT cases were enrolled in the study (202 and 146 in the pre- and post-intervention group, respectively). The median age was 61 years in both groups; 25.2% and 26.7% of patients in the pre- and post-intervention groups, respectively, were female. The post-intervention group had higher rates of dyslipidemia and minor stroke [defined as National Institutes of Health Stroke Scale (NIHSS) ≤ 3]; less frequent atrial fibrillation; higher numbers of current smokers, heavy drinkers, referrals, and multi-model head imaging cases; and lower NIHSS scores and blood sugar level (all P < 0.05). All parameters including DTN, door-to-examination, door-to-imaging, door-to-laboratory, and final-test-to-needle times were improved post-intervention (all P < 0.05), with net reductions of 63, 2, 4, 28, and 23 min, respectively. The rates of DTN time ≤ 60 min and onset-to-needle time ≤ 180 min were significantly improved by the intervention (pre: 9.9% vs. post: 60.3%; P < 0.001 and pre: 23.3% vs. post: 53.4%; P < 0.001, respectively), which was accompanied by an increase in the rate of neurological improvement (pre: 45.5% vs. post: 59.6%; P = 0.010), while there was no change in incidence of mortality or systemic intracranial hemorrhage at discharge (both P > 0.05). These findings indicate that it is possible to achieve a DTN time ≤ 60 min for up to 60% of hospitals in the current Chinese system, and that this logistical change can yield a notable improvement in the outcome of IVT patients.

Highlights

  • Intravenous thrombolysis (IVT) is one of the most efficacious treatments for acute ischemic stroke (AIS), for which therapeutic intervention is highly time-sensitive [1,2,3]

  • Less than half of American [4] and even fewer Chinese [5,6] patients with AIS are treated with recombinant tissue plasminogen activator within the time frame recommended by the American Heart Association and American Stroke Association [door-to-needle (DTN) time 60 min] [7], which has been validated by the Get With The Guidelines—Stroke program [8]

  • Strategies for reducing in-hospital delays of IVT administration have been implemented in many Western institutions [4,9,10,11,12] and the median DTN time has been reduced to < 20 min in at least one stroke center [10], this has not been the case in most Chinese hospitals [5,6], which may be attributed to differences between the Chinese healthcare system and those of Western countries [13]

Read more

Summary

Introduction

Intravenous thrombolysis (IVT) is one of the most efficacious treatments for acute ischemic stroke (AIS), for which therapeutic intervention is highly time-sensitive [1,2,3]. Strategies for reducing in-hospital delays of IVT administration have been implemented in many Western institutions [4,9,10,11,12] and the median DTN time has been reduced to < 20 min in at least one stroke center [10], this has not been the case in most Chinese hospitals [5,6], which may be attributed to differences between the Chinese healthcare system and those of Western countries [13]. In the present historical controlled study, we investigated the efficacy and safety of various strategies for reducing DTN time at a tertiary hospital in China

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.